eatris European infrastructure for translational medicine

Want to accelerate your small molecules development towards the clinic?

Therapeutic innovation is driven by novel drug development concepts and platform technologies, while increasingly patient-centric in addressing unmet medical need. New collaborative models are key to tackle the challenges in drug development and enable faster, affordable, and personalised therapeutic solutions.

The EATRIS Small Molecules Platform offers academic drug development expertise and advanced technological infrastructure from preclinical to clinical proof of concept using predictive models, studying disease mechanisms and unlocking the potential of drug repurposing.

What can EATRIS offer the small molecules developer?

- 37+ top-tier translational and clinical research centres experienced in advanced drug screening, preclinical development and clinical trials with innovative therapeutics.
- Latest platform technologies with preclinical and clinical assessment of safety and efficacy of new molecular entities.
- Access to clinical and disease expertise with a patient-centric approach.
- A growing and globally connected community of practice in drug repurposing to address high unmet medical needs and expand therapeutic uses for existing medicines in regulatory compliant, cost-effective and sustainable manner.

What services can we provide?

Predictive models (3D culture systems, organoids, spheroids, patient-derived xenografts and in vivo animal models, including non-human primates)	Platform technologies (e.g.,oligonuclotides, nanomedicines, n of 1 trials, repurposing)	Advanced drug screening (HTS, phenotypic and high content) using iPSC, cell painting and 3D models.
Predictive in vitro and in vivo models linked to disease expertise, MoA studies	Clinical trial centres for Phase I/II studies in University Medical Centres (interaction between clinicians and scientists)	Drug (re)formulation, including nanoparticles
Innovation platform supporting promising, high impact drug repurposing projects championed by patients in any phase of development and disease	In silico prediction tools (ADME, safety, tox, synergies)	Chemosensitivity screening in clinical setting (e.g. oncology, drug resistance)
Expertise in pharmacology, medicinal, CMC and analytical chemistry	Access to patient materials and cohorts	Regulatory expertise (scientific advice, TPPP and IMPD development) and regulatory science approaches

Looking for something else?

Contact Martin de Kort, Senior Scientific Programme Manager: martindekort@eatris.eu

Or find us online:

eatris.eu EatrisEric eatris-eric EATRIS-ERIC EATRIS.ERIC